# Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00068432** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Gemcitabine Hydrochloride

## Key facts

- **NCT ID:** NCT00068432
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068432, "Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00068432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*